Synedgen
Synedgen is a biopharmaceutical company focused on developing therapeutics that enhance mucosal barrier function and repair injuries, with its leading product, MIIST305, targeting GI mucosal damage.
Company Overview
Synedgen develops first-in-class therapeutics that improve patient outcomes by promoting barrier function to repair mucosal injury. The company has a strong intellectual property position with a broad US and international patent estate.
Lead Asset: MIIST305
Synedgen's current lead asset is MIIST305, a clinic-ready, orally delivered therapeutic designed to repair gastrointestinal (GI) mucosal injury. MIIST305 restores GI function and reduces unchecked inflammation and damage. The company has completed IND-enabling studies for two parallel programs focused on MIIST305.
Pilot Clinical Trials and Other Programs
Beyond its lead asset, Synedgen has completed pilot clinical trials for a sinus health product. The company's therapeutics have demonstrated efficacy across multiple modalities, and it continues to develop targeted therapies with scalable GMP production and excellent safety profiles.
Partnerships and Funding
The development of Synedgen’s MIIST platform has been aided by extensive funding from the U.S. Army, DARPA, and other partners. Additionally, Synedgen has been awarded a 3-year grant from the National Eye Institute (NEI) of the NIH to develop molecules for severe, ulcerative eye injury.